That Time Snoop Dogg Ate Mushrooms and Cried Backstage
“I don’t even know what got into my emotions, but I felt so good, and the crying just made me feel even better,” the Super Bowl halftime show performer says.
Author: Greg Gilman
Psychedelic Business Spotlight – February 4
Levitee Labs Announces Interim CEO and Board of Directors Shuffle…
Psychedelic Business Spotlight — January 28
This week in psychedelic business news: A major player begins manufacturing; another rebrands; and one of the biggest gets bigger.
How Rick Doblin Guides Someone Through a Bad Psychedelic Trip
Difficult trips could be a problem in areas where psychedelics have been decriminalized, which is why MAPS will offer a psychonaut training program.
Psychedelic Business Spotlight – January 21
Catch up on some of the biggest psychedelic business developments that unfolded in the last week.
DEA Proposes Adding 5 More Psychedelics to Schedule 1 Controlled Substances
Agency argues these five tryptamines “have no known medical use,” setting up a showdown with the emerging psychedelics industry.
Majority of Mental Health Patients Support Access to Psychedelics, Survey Finds
Americans continue to open their minds to ketamine, psilocybin, and MDMA treatment for depression, anxiety, and PTSD.
Psychedelics Will Have a Big Presence at SXSW in 2022
Tim Ferriss and Roland Griffiths are among the biggest names in the burgeoning psychedelics movement that are set to appear during the SXSW Conference running from March 11-20.
Mindset Pharma Teams Up with The McQuade Center to Develop 2 Families of Novel Psychedelic Compounds
It’s yet another sign that the pharmaceutical industry at large is taking the potential of psychedelics very seriously.
Health Canada Grants Special Access to Restricted Drugs for Psychedelic Therapy
New amendment reverses a 2013 Health Canada policy that prevented “a letter of authorization for a new drug that is or that contains a restricted drug.”
End of content
End of content